株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

大容量ウェアラブルインジェクター市場

Large Volume Wearable Injectors (2nd Edition)

発行 ROOTS ANALYSIS 商品コード 312919
出版日 ページ情報 英文 242 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: ROOTS ANALYSIS社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
大容量ウェアラブルインジェクター市場 Large Volume Wearable Injectors (2nd Edition)
出版日: 2014年09月15日 ページ情報: 英文 242 Pages
概要

多くの生物製剤が現在開発中であり、それらの分子の大半は粘性が高く、1ml以上の量を投与しなければなりません。そこでこうした分子の自己投与を可能とする装置が業界ステークホルダーに普及しようとしています。生物製剤市場の成長が大容量ウェアラブルインジェクター市場の発展を促進するひとつの要因となっています。

当レポートは、大容量ウェアラブルインジェクター市場の現状と今後10年間の予測、現在のアンメットニーズなどについてまとめています。

エグゼクティブサマリー

第1章 序論

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 本章の概要
  • 従来のニードルとシリンジによるデリバリー
  • 薬剤自己投与
    • 慢性疾患の負担増大
    • 自己投与に利用可能なシステム
  • 針先損傷
    • 発生率と費用負担
    • 針先損傷予防のための政府法規制
  • セルフインジェクターの安全策

第4章 概要および市場の背景

  • 本章の概要
  • ウェアラブルインジェクターとは
  • ウェアラブルインジェクターのニーズ
  • ウェアラブルインジェクターの種類
  • 大容量ウェアラブルインジェクターの範囲
  • 大容量ウェアラブルインジェクターの構成要素
  • 大容量ウェアラブルインジェクターの分類
  • 開発中の大容量ウェアラブルインジェクター
  • 大容量ウェアラブルインジェクター市場促進因子

第5章 大容量ウェアラブルインジェクターのための標的薬剤

  • 本章の概要
  • 生物製剤市場

第6章 ケーススタディ

第7章 製品プロファイル

第8章 市場規模と予測

第9章 SWOT分析

第10章 企業プロファイル

  • Unilife Corporation
  • west Pharmaceutical Services
  • BD Medical
  • Sensile Medical AG
  • SteadyMed Therapeutics
  • Ratio, Inc
  • Valeritas Inc.
  • Roche Laboratories
  • CeQur
  • Calibra Medical
  • Batelle

第11章 インタビュー原稿

第12章 結論

第13章 付録1:表形式データ

第14章 付録2:企業・組織リスト

図表

目次
Product Code: RA10022

The injectable drug delivery market holds significant potential for the future. From the conventional syringes with vials and painful needles to the modern-day pre-filled syringes, pen-injectors, needle free injectors and auto-injectors, the market has come a long way. The rising prevalence of chronic diseases is one of the key factors driving the companies to develop systems that allow patients to self-administer drugs. Taking the concept of self-injectors to a new stratum, ‘Large volume Wearable Injectors' have surfaced recently. Also known as bolus injectors and non-insulin patch pumps, these devices not only offer a range of benefits to the end users but also provide a number of additional benefits to other stakeholders in the industry.

One of the main drivers for the perceived growth of these injectors is the large number of biologics currently under development. A majority of these molecules are highly viscous and are required to be delivered in volumes of greater than 1 ml. The absence of devices which can safely administer these drugs is currently a big unmet need in the market. However, the early signs are encouraging. Despite the uncertainties related to the device development and approval, many companies are investing time, money and resources to develop novel devices. Some customized drug-device combinations are currently being developed for specific drugs such as Herceptin, AMG-145 and Furosemide. In addition, pharma companies have many undisclosed programs which are likely to provide the necessary growth impetus in the near future.

This development is being led jointly by established firms such as Becton Dickinson, West Pharmaceuticals and emerging players such as Unilife, SteadyMed Therapeutics, Ratio Drug Delivery, Sensile Medical, Enable Injections and scPharmaceuticals. It is widely anticipated that, once ready, such devices which will allow self-administration of high viscosity, large volume biologics and be readily adopted in the industry.

Synopsis:

The ‘Large Volume Wearable Injectors' market report provides a comprehensive analysis of the current state of the market and the likely future evolution over the next ten years. Starting with the basic introduction to these injectors, the report lays emphasis on the current unmet needs of the market. As all the large volume wearable injectors are currently only available for investigational use, the investment being done in this area is geared towards tapping the significant future potential of this market. In fact, one of the primary objectives of this report is to estimate the size of this future promise offered by such injectors.

A large number of biologics are currently under development and a majority of these molecules are highly viscous and require to be delivered in volumes of greater than 1 ml. It is widely anticipated that devices which will allow self-administration of these molecules will be readily adopted by all stakeholders in the industry. For the purposes of our analysis, we followed a top-down approach to estimate the size of this market. This included:

  • Conducting an extensive research to identify high viscosity and large volume biologics which are either currently under development or are already marketed.
  • Based on the standard dosage regime and the likely injection frequency, shortlisting the highly likely candidates for delivery via bolus injectors.
  • For these molecules under development, estimating the likely timeline by when they will be ready for subcutaneous administration.
  • Estimating the proportion of these molecules which will be available for subcutaneous delivery via large volume wearable injectors for around 14 disease classes.
  • Estimating the sales potential (both in terms of value and volume) of these injectors for each drug-disease combination over the next ten years.

Where possible, we have added robustness to our forecasting model by conducting extensive primary research interviews with senior stakeholders in the industry. Owing to the uncertain nature of the market, we have provided three scenarios for our market forecast. The conservative, base and optimistic scenarios are considered for the forecasting of each of the analysed drug-disease combinations and represent three different tracks of industry evolution.

Example Highlights

  • 1. In total, over 15 large volume wearable drug delivery devices (including variants) currently under development have been identified during our research.
  • 2. Approximately 53% of these devices operate electronically. Other modes of operation include mechanical, hydrogel and hydraulic. Many of these injectors have additional features such as an audio / visual panel making their usage very easy for the end users.
  • 3. The range of volume these devices can cater to is as high as 30 ml. The first commercial launch is anticipated to take place in 2015/2016. In our research, we have profiled five drugs which are currently undergoing trials for delivery via large volume injectors.
  • 4. Pharma companies also have many undisclosed research programs.We have identified about 30 biologics which are likely to be immediate targets for preparation of subcutaneous formulation and delivery via large volume wearable injectors. In addition to these highly likely candidates, there are more than 100 other drug-disease combinations which are expected to draw interest in the short-mid term.
  • 5. The manufacturer's landscape is still evolving. In addition the established firms such as Becton Dickinson and West Pharma, many start-ups including Unilife, Sensile Medical, SteadyMed Therapeutics and Enable Injections are heading towards the pole position
  • 6. The growth in biologics will be one of the key drivers for the emergence of large volume wearable injectors. Around 50% of the top 100 selling drugs are expected to be biologics by 2016; biologics are estimated to contribute 27% of the total drugs market by 2020.
  • 7. Other key reasons for the growth of bolus injectors include their potential to act as life cycle management tool, increasing trend towards drug self-administration and the overall drive towards cheaper healthcare costs.

Research Methodology

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Other analysts' opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of the bolus injectors market.

Chapter 3 provides a general introduction to the market and the historical evolution of self-administration injection devices. The chapter also talks about needlestick injuries and the growing preference towards safe and easy-to-use devices.

Chapter 4 provides a detailed overview on wearable injectors and the various unmet needs which are fuelling the rise of these injectors. It not only provides a detailed introduction to large volume wearable injectors but also highlights their key features and categorises the various large volume wearable injectors (currently under development) by mode of operation, device usage and volume.

Chapter 5 highlights the various molecules which are likely to form the target market of large volume wearable injectors. It also looks at the likely growth of biologics market over the next ten years; this is expected to be a significant driver for the large volume wearable injectors which are likely to become the preferred device for delivery of high viscous, large volume biologics.

Chapter 6 provides detailed case studies on five drugs being targeted to deliver through bolus injectors/patch pumps.

Chapter 7 includes detailed profiles of various large volume wearable injectors, their applications, usage mechanism and current state of development.

Chapter 8 looks at the future state of large volume wearable injectors market till 2025. It highlights the leading disease classes which will drive this growth and the relative market size of large volume wearable injectors within each disease class, both in terms of the number of units and the value of the market.

Chapter 9 provides the SWOT analysis of large volume wearable injectors market giving strategic insights to the major factors that are likely to contribute to the growth while also highlighting the weakness and threats that can negatively impact the growth.

Chapter 10 includes profiles of the key companies in the large volume wearable injectors market. Each company profile includes information such as financial performance, marketed / pipeline products, recent developments and future growth plans.

Chapter 11 is a collection of transcripts of some of the interviews which were conducted while preparing this report.

Chapter 12 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in the previous chapters.

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures presented in the report.

Chapter 14 is an appendix, which provides a list of companies and organisations mentioned in this report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Conventional Needle and Syringe Delivery
  • 3.3. Self-administration of Drugs
    • 3.3.1. Rising Burden of Chronic Diseases
    • 3.3.2. Systems Available for Self-administration
  • 3.4. Needlestick Injuries
    • 3.4.1. Incidence and Cost Burden
    • 3.4.2. Government Legislation for Needlestick Injury Prevention
  • 3.5. Safety Options in Self Injectors

4. OVERVIEW AND MARKET BACKGROUND

  • 4.1. Chapter Overview
  • 4.2. What Are Wearable Injectors
  • 4.3. The Need for Wearable Injectors
    • 4.3.1. Advancements in Drug Classes
    • 4.3.2. Need for Better Patient Compliance
  • 4.4. Types of Wearable Injectors
    • 4.4.1. Insulin Pumps with Infusion Sets
    • 4.4.2. Insulin Patch Pumps
    • 4.4.3. Transdermal Patch
    • 4.4.4. Bolus Injectors
  • 4.5. Our Scope of Large Volume Wearable Injectors
  • 4.6. Components of a Large Volume Wearable Injector
  • 4.7. Classification of Large Volume Wearable Injectors
    • 4.7.1. Mechanism Based Classification
    • 4.7.2. Usage Based Classification
    • 4.7.3. Drug Delivery Based Classification
    • 4.7.4. Volume Based Classification
  • 4.8. Large Volume Wearable Injectors Under Development
    • 4.8.1. Distribution by Mode of Operation
    • 4.8.2. Distribution by Device Usage
    • 4.8.3. Distribution by Volume
  • 4.9. Factors Driving the Large Volume Wearable Injectors Market
    • 4.9.1. Growth of Biologics and Biosimilars
    • 4.9.2. Life Cycle Management Activities Driving Demand for Alternative Delivery Systems
    • 4.9.3. Need for Brand Differentiation
    • 4.9.4. Drive towards Cheaper Healthcare Costs
    • 4.9.5. Convenient Drug Reconstitution
    • 4.9.6. Interest from Multinational Pharmaceutical Companies

5. TARGET DRUGS FOR LARGE VOLUME WEARABLE INJECTORS

  • 5.1. Chapter Overview
  • 5.2. Biologics Market
    • 5.2.1. Biologics Market Forecast, 2014-2020
    • 5.2.2. Biologics Market Trends
    • 5.2.3. Biologics: Likely Targets for Large Volume Wearable Injectors

6. CASE STUDIES

  • 6.1. Chapter Overview
  • 6.2. Case Study: Herceptin (Genentech/Roche)
    • 6.2.1. Background and History of Development
    • 6.2.2. Indications and Dosage Forms
    • 6.2.3. Target Population
    • 6.2.4. Sales, 1999 - 2013
    • 6.2.5. Launch of Subcutaneous Formulation
    • 6.2.6. ENHANZE™: The Technology Behind Subcutaneous Formulation of Herceptin (Halozyme Therapeutics)
    • 6.2.7. Advantages of Subcutaneous Form Over Intravenous
    • 6.2.8. Herceptin Likely to be the First Biologic to be Launched in Bolus Injector
  • 6.3. Case Study: Furosemide and Cephalosporin (scPharmaceuticals)
    • 6.3.1. Furosemide
      • 6.3.1.1. Background and History of Development
      • 6.3.1.2. Dosage Forms
      • 6.3.1.3. Sales 2010-2012
      • 6.3.1.4. Advantages of Subcutaneous Form Over Intravenous delivery of furosemide
    • 6.3.2. Cephalosporin
      • 6.3.2.1. Background and History of Development
      • 6.3.2.2. Dosage Forms
    • 6.3.3. scPharmaceuticals and Sensile Medical Strategic Partnership
    • 6.3.4. The Technology Behind Subcutaneous administration of furosemide and cephalosporin
  • 6.4. Case Study: Evolocumab / AMG 145 (Amgen)
    • 6.4.1. History of Development
    • 6.4.2. Current Status
    • 6.4.3. Indications and Dosage Forms
    • 6.4.4. Target Population
    • 6.4.5. Future Plans
  • 6.5. Case Study: ND0612L (NeuroDerm)
    • 6.5.1. Background and History of Development
    • 6.5.2. Dosage Forms
    • 6.5.3. Target Population
    • 6.5.4. Sales
    • 6.5.5. Levodopa/Carbidopa Subcutaneous Administration through a Patch Pump

7. PRODUCT PROFILES

  • 7.1. Chapter Overview
  • 7.2. MyDose (Roche)
    • 7.2.1. Introduction
    • 7.2.2. Product Description
    • 7.2.3. Usage / Mechanism
    • 7.2.4. Advantages
    • 7.2.5. Manufacturing of MyDose
    • 7.2.6. Current Status
  • 7.3. BD Libertas™ Patch Injector (BD MEDICAL, A Segment of Becton Dickinson and Company)
    • 7.3.1. Introduction
    • 7.3.2. Product Description
    • 7.3.3. Usage / Mechanism
    • 7.3.4. Advantages
    • 7.3.5. Current Status
  • 7.4. SmartDose (West Pharmaceutical Services, Inc.)
    • 7.4.1. Introduction
    • 7.4.2. Product Description
    • 7.4.3. Usage / Mechanism
    • 7.4.4. Advantages
    • 7.4.5. Current Status
  • 7.5. Precision-Therapy™ and Flex-Therapy™ (Unilife Corporation)
    • 7.5.1. Introduction
    • 7.5.2. Product Description
    • 7.5.3. Usage / Mechanism
    • 7.5.4. Advantages
    • 7.5.5. Current Status
  • 7.6. PatchPump® (SteadyMed Therapeutics)
    • 7.6.1. Introduction
    • 7.6.2. Product Description
    • 7.6.3. Usage / Mechanism
    • 7.6.4. Advantages
    • 7.6.5. Evaluating the Device for In-House Drugs
    • 7.6.6. Current Status
  • 7.7. SenseBolus, SensePatch and SenseTrial (Sensile Medical AG)
    • 7.7.1. Introduction
    • 7.7.2. Product Description
    • 7.7.3. SenseBolus SD
    • 7.7.4. SensePatch (SD and FD)
    • 7.7.5. SenseTrial SD
    • 7.7.6. Usage / Mechanism
    • 7.7.7. Advantages
    • 7.7.8. Current Status
  • 7.8. NuPrivo-SC and NuPrivo-CI (Ratio, Inc.)
    • 7.8.1. Introduction
    • 7.8.2. Product Description
      • 7.8.2.1. NuPrivo-SC
      • 7.8.2.2. NuPrivo-CI
    • 7.8.3. Advantages of NuPrivo-SC and NuPrivo-CI
    • 7.8.4. Current Status
  • 7.9. Rapid Infuser and V-Go (Valeritas, Inc.)
    • 7.9.1. Introduction
    • 7.9.2. Rapid Infuser
      • 7.9.2.1. Advantages
    • 7.9.3. V-Go
      • 7.9.3.1. Advantages
    • 7.9.4. Current Status
  • 7.10. Enable Injector (Enable Injections)
    • 7.10.1. Introduction
    • 7.10.2. Product Description
    • 7.10.3. Usage/Mechanism
    • 7.10.4. Advantages
    • 7.10.5. Current Status
  • 7.11. Finesse™ (Calibra Medical)
    • 7.11.1. Introduction
    • 7.11.2. Product Description
    • 7.11.3. Usage/Mechanism
    • 7.11.4. Advantages
    • 7.11.5. Current Status
  • 7.12. PaQ™ (CeQur)
    • 7.12.1. Introduction
    • 7.12.2. Product Description
    • 7.12.3. Usage/Mechanism
    • 7.12.4. Advantages
    • 7.12.5. Current Status

8. MARKET SIZE AND FORECAST

  • 8.1. Chapter Overview
  • 8.2. Forecast Methodology
  • 8.3. Overall Large Volume Wearable Injectors Market, 2014 - 2025
  • 8.4. Large Volume Wearable Injectors for Cancer and Related Conditions, 2014 - 2025
  • 8.5. Large Volume Wearable Injectors for Autoimmune Diseases, 2014 - 2025
  • 8.6. Large Volume Wearable Injectors for Blood Disorders, 2014 - 2025
  • 8.7. Large Volume Wearable Injectors for Genetic Disorders, 2014 - 2025
  • 8.8. Large Volume Wearable Injectors for Infectious Diseases, 2014 - 2025
  • 8.9. Large Volume Wearable Injectors for Cardiovascular Diseases, 2014 - 2025
  • 8.10. Large Volume Wearable Injectors for Respiratory Disorders, 2014 - 2025
  • 8.11. Large Volume Wearable Injectors for Digestive Disorders, 2014 - 2025
  • 8.12. Large Volume Wearable Injectors for Musculoskeletal Disorders, 2014 - 2025
  • 8.13. Large Volume Wearable Injectors for Diabetes, 2014 - 2025
  • 8.14. Large Volume Wearable Injectors for Eye Conditions, 2014 - 2025
  • 8.15. Large Volume Wearable Injectors for Skin Diseases, 2014 - 2025
  • 8.16. Large Volume Wearable Injectors for Neurologic Disorders, 2014 - 2025
  • 8.17. Large Volume Wearable Injectors for Other Diseases, 2014 - 2025

9. SWOT ANALYSIS

  • 9.1. Overview
  • 9.2. Strengths
    • 9.2.1. Greater Flexibility in Dosage Volume and Time of Delivery
    • 9.2.2. Consistent Drug Delivery
    • 9.2.3. Benefits to Other Stakeholders in the Value Chain
      • 9.2.3.1. Benefits to Payers
      • 9.2.3.2. Benefits to Pharmaceutical Companies
  • 9.3. Weaknesses
    • 9.3.1. Newness and Uncertainty
    • 9.3.2. Product Stability
    • 9.3.3. Fill/Finish Complexities
  • 9.4. Opportunities
    • 9.4.1. Growth of Biologics and Biosimilars
    • 9.4.2. Venture Capital Interest
    • 9.4.3. Life Cycle Management Tool
    • 9.4.4. Paediatric and Geriatric Population
  • 9.5. Threats
    • 9.5.1. Alternative Drug Delivery Systems: Autoinjectors and Pen Injectors
    • 9.5.2. Alternative Drug Delivery Systems: Other Wearable Injectors
    • 9.5.3. Case Study: Treprostinil (SteadyMed)
      • 9.5.3.1. Background and History of Development
      • 9.5.3.2. Indications and Dosage Forms
      • 9.5.3.3. Target Population
      • 9.5.3.4. Drug Sales
      • 9.5.3.5. Advantages of Subcutaneous Treprostinil
      • 9.5.3.6. Trevyent™ Patch Pump for subcutaneous administration of Treprostinil
      • 9.5.3.7. Current Status
    • 9.5.4. History of Device Recalls
    • 9.5.5. Reimbursement From Public/Private Healthcare Services
    • 9.5.6. Material Compatibility Issues

10. COMPANY PROFILES

  • 10.1. Unilife Corporation
    • 10.1.1. Overview and Background
    • 10.1.2. Financial Performance
    • 10.1.3. Product Portfolio
      • 10.1.3.1. Unifill Platform of Prefilled Syringes
      • 10.1.3.2. EZMix Platform of Dual-Chamber Syringes (Drug Reconstitution Delivery Systems)
      • 10.1.3.3. Auto-Injector Platform
      • 10.1.3.4. Wearable Injector Platform
      • 10.1.3.5. Ocular Delivery Systems
      • 10.1.3.6. Novel Delivery Systems
    • 10.1.4. Recent Developments
      • 10.1.4.1. Partnership with Novartis
      • 10.1.4.2. Partnership with Global Pharmaceutical Company (undisclosed)
      • 10.1.4.3. Partnership with MedImmune
      • 10.1.4.4. Partnership with Hikma
      • 10.1.4.5. Partnership with Sanofi
      • 10.1.4.6. Partnership with Biodel
    • 10.1.5. Future Growth Plans
  • 10.2. west Pharmaceutical Services
    • 10.2.1. Overview and Background
    • 10.2.2. Financial Performance
    • 10.2.3. Product Portfolio
      • 10.2.3.1. Marketed Products
      • 10.2.3.2. Pipeline Products
    • 10.2.4. Recent Developments
      • 10.2.4.1. Advancing the Growth of CZ Syringes
      • 10.2.4.2. Looking to Grow in Pharmerging markets (Brazil, China and India)
      • 10.2.4.3. Agreement with Janssen Biotech
    • 10.2.5. Future Growth Plans
  • 10.3. BD Medical, A Segment Of Becton, Dickinson and Company
    • 10.3.1. Overview and Background
    • 10.3.2. Financial Performance
    • 10.3.3. Product Portfolio
      • 10.3.3.1. Marketed Products
      • 10.3.3.2. Pipeline Products
    • 10.3.4. Recent Developments
      • 10.3.4.1. Agreement with Biodel
      • 10.3.4.2. Collaboration with World Health Organization (WHO)
      • 10.3.4.3. Launch of BD Sterifill Advance™
      • 10.3.4.4. Entering the Generic Business
      • 10.3.4.5. Acquisition of Cato Software Solution
      • 10.3.4.6. Acquisition of Safety Syringes
    • 10.3.5. Future Growth Plans
  • 10.4. Sensile Medical AG
    • 10.4.1. Overview and Background
    • 10.4.2. Product Portfolio
    • 10.4.3. Technology Portfolio
    • 10.4.4. Recent Developments
    • 10.4.5. Future Growth Plans
  • 10.5. SteadyMed Therapeutics
    • 10.5.1. Overview and Background
    • 10.5.2. Financial Performance
    • 10.5.3. Product Portfolio
    • 10.5.4. Technology Portfolio
    • 10.5.5. Recent Developments
    • 10.5.6. Future Growth Plans
  • 10.6. Ratio, Inc.
    • 10.6.1. Overview and Background
    • 10.6.2. Financial Performance
    • 10.6.3. Product Portfolio
    • 10.6.4. Technology Portfolio
    • 10.6.5. Recent Developments
    • 10.6.6. Future Growth Plans
  • 10.7. Valeritas Inc.
    • 10.7.1. Overview and Background
    • 10.7.2. Financial Performance
    • 10.7.3. Product Portfolio
    • 10.7.4. Technology Portfolio
      • 10.7.4.1. h-Patch™
      • 10.7.4.2. Mini-Ject™
      • 10.7.4.3. Micro-Trans™
    • 10.7.5. Recent Developments
  • 10.8. Roche Laboratories
    • 10.8.1. Overview and Background
    • 10.8.2. Financial Performance
    • 10.8.3. Product Portfolio
    • 10.8.4. Recent Developments
      • 10.8.4.1. Approval for MabThera
      • 10.8.4.2. Approval for Herceptin
      • 10.8.4.3. ISPE Facility of the Year Award
    • 10.8.5. Future Growth Plans
  • 10.9. CeQur
  • 10.10. Calibra Medical
  • 10.11. Batelle

11. INTERVIEW TRANSCRIPTS

  • 11.1. Interview 1: Ben Moga, President, Ratio Drug Delivery
  • 11.2. Interview 2: Anonymous, West Pharmaceutical Services
  • 11.3. Interview 3: Michael Hooven, CEO, Enable Injections
  • 11.4. Interview 4: Pieter Muntendam, CEO, scPharmaceuticals

12. CONCLUSION

  • 12.1. An Emerging Market Ready to Explode
  • 12.2. Growth of Biologics will be the Single Biggest Driver
  • 12.3. Venture Capital Interest Likely to Stay High
  • 12.4. The Handful of Drug-Device Combination currently in the research pipeline will be the first generation of Large Volume Wearable Injectors
  • 12.5. Concluding Remarks

13. APPENDIX 1: Tabulated Data

14. APPENDIX 2: List of Companies and Organizations

List of Figures

  • Figure 3.1: Prevalence of Diabetes, 2013 - By Countries (%)
  • Figure 4.1: Benefits of Large Volume Wearable Injectors to Stakeholders
  • Figure 4.2: Large Volume Wearable Injectors: Distribution by Modes of Operation
  • Figure 4.3: Large Volume Wearable Injectors: Distribution by Device Usage
  • Figure 4.4: Large Volume Wearable Injectors: Distribution by Volume
  • Figure 5.1: Total Drugs Market, 2013 - By Nature of Drug (USD Billion, %)
  • Figure 5.2: Drugs Market Forecast, 2014-2020: Distribution by Biologics and Pharmaceuticals (USD Billion)
  • Figure 5.3: Biologic Drugs in Development, 2012: Distribution by Type of Molecule (%)
  • Figure 6.1: HER2 Expression in Breast Cancer Patients (%)
  • Figure 6.2: Herceptin Sales, 1999 - 2013 (CHF Million)
  • Figure 6.3: Worldwide Furosemide Sales, 2010-2012 (USD Million)
  • Figure 6.4: Carbidopa/Levodopa Worldwide Sales, 2010-2012 (USD, Million)
  • Figure 8.1: Overall Large Volume Wearable Injectors Market (Number of Devices, Millions), 2014 - 2025
  • Figure 8.2: Overall Large Volume Wearable Injectors Market (USD Million), 2014 - 2025
  • Figure 8.3: Number of Molecules in Large Volume Wearable Injectors for Cancer and Related Conditions (2014 - 2025)
  • Figure 8.4: Large Volume Wearable Injectors Market for Cancer and Related Conditions (Number of Devices, Millions), 2014 - 2025
  • Figure 8.5: Number of Molecules in Large Volume Wearable Injectors for Autoimmune Diseases (2014 - 2025)
  • Figure 8.6: Large Volume Wearable Injectors Market for Autoimmune Diseases (Number of Devices, Millions), 2014 - 2025
  • Figure 8.7: Number of Molecules in Large Volume Wearable Injectors for Blood Disorders (2014 - 2025)
  • Figure 8.8: Large Volume Wearable Injectors Market for Blood Disorders (Number of Devices, Millions), 2014 - 2025
  • Figure 8.9: Number of Molecules in Large Volume Wearable Injectors for Genetic Disorders (2014 - 2025)
  • Figure 8.10: Large Volume Wearable Injectors Market for Genetic Disorders (Number of Devices, Millions), 2014 - 2025
  • Figure 8.11: Number of Molecules in Large Volume Wearable Injectors for Infectious Diseases (2014 - 2025)
  • Figure 8.12: Large Volume Wearable Injectors Market for Infectious Diseases (Number of Devices, Millions), 2014 -2025
  • Figure 8.13: Number of Molecules in Large Volume Wearable Injectors for Cardiovascular Diseases (2014 - 2025)
  • Figure 8.14: Large Volume Wearable Injectors Market for Cardiovascular Diseases (Number of Devices, Millions), 2014 - 2025
  • Figure 8.15: Number of Molecules in Large Volume Wearable Injectors for Respiratory Disorders (2014 - 2025)
  • Figure 8.16: Large Volume Wearable Injectors Market for Respiratory Disorders (Number of Devices, Millions), 2014 - 2025
  • Figure 8.17: Number of Molecules in Large Volume Wearable Injectors for Digestive Disorders (2014 - 2025)
  • Figure 8.18: Large Volume Wearable Injectors Market for Digestive Disorders (Number of Devices, Millions), 2014 - 2025
  • Figure 8.19: Number of Molecules in Large Volume Wearable Injectors for Musculoskeletal Disorders (2014 - 2025)
  • Figure 8.20: Large Volume Wearable Injectors Market for Musculoskeletal Disorders (Number of Devices, Millions), 2014 - 2025
  • Figure 8.21: Number of Molecules in Large Volume Wearable Injectors for Diabetes (2014 - 2025)
  • Figure 8.22: Large Volume Wearable Injectors Market for Diabetes (Number of Devices, Millions), 2014 - 2025
  • Figure 8.23: Number of Molecules in Large Volume Wearable Injectors for Eye Conditions (2014 - 2025)
  • Figure 8.24: Large Volume Wearable Injectors Market for Eye Conditions (Number of Devices, Millions), 2014 - 2025
  • Figure 8.25: Number of Molecules in Large Volume Wearable Injectors for Skin Diseases (2014 - 2025)
  • Figure 8.26: Large Volume Wearable Injectors Market for Skin Diseases (Number of Devices, Millions), 2014 - 2025
  • Figure 8.27: Number of Molecules in Large Volume Wearable Injectors for Neurologic Disorders (2014 - 2025)
  • Figure 8.28: Large Volume Wearable Injectors Market for Neurologic Disorders (Number of Devices, Millions), 2014 - 2025
  • Figure 8.29: Number of Molecules in Large Volume Wearable Injectors for Other Diseases (2014 - 2025)
  • Figure 8.30: Large Volume Wearable Injectors Market for Other Diseases (Number of Devices, Millions), 2014 - 2025
  • Figure 9.1: Number of Biologics Approved by the US FDA, 2009-2013
  • Figure 9.2: Remodulin Sales by United Therapeutics, 2007-2013 (USD Million)
  • Figure 9.3: Tyvaso Sales by United Therapeutics, 2009-2013 (USD Million)
  • Figure 10.1: Revenues, Unilife Corporation, FY 2011 - FY 2013 (USD ‘000)
  • Figure 10.2: West Pharmaceutical Services, 2011-2013, Sales by Business Divisions (USD Million, %)
  • Figure 10.3: BD Medical, 2011-2013- Sales by Business Divisions (USD Billion, %)
  • Figure 10.4: Roche Annual Sales, 2009-2013 (CHF Million)
  • Figure 10.5: Roche Annual Sales, 2013: Distribution by Business Segment (CHF Million)
  • Figure 10.6: Roche Pharmaceuticals Annual Sales, 2013: Distribution by Segment (%)
  • Figure 12.1: Large Volume Wearable Injectors Market (Number of Devices, Millions): 2016, 2020, 2025
  • Figure 12.2: Large Volume Wearable Injectors Market (USD Million): 2016, 2020, 2025

List of Tables

  • Table 4.1: Traditional Pump Devices vs. Large Volume Wearable Injectors
  • Table 4.2: Large Volume Wearable Injectors: Benefits v/s Perceived Issues
  • Table 4.3: Large Volume Wearable Injectors Under Development
  • Table 5.1: Biologics Under Consideration for Large Volume Wearable Injectors: Most Likely Candidates
  • Table 5.2: Biologics Under Consideration for Large Volume Wearable Injectors: Likely Candidates
  • Table 5.3: Biologics Under Consideration for Large Volume Wearable Injectors: Less Likely Candidates
  • Table 5.4: Biologics Under Consideration for Large Volume Wearable Injectors: Other Candidates
  • Table 6.1: Drugs Under Development for Delivery Through Large Volume Wearable Injectors
  • Table 6.2: Furosemide Manufacturers, 2014
  • Table 6.3: Cephalosporin Classification by Generation
  • Table 6.4: Evolocumab: Completed Phase III Studies
  • Table 6.5: Evolocumab: Some Ongoing Clinical Trials
  • Table 6.6: List of Some Manufacturers of Levodopa/Carbidopa Fixed Combinations
  • Table 7.1: Clinical Trials Evaluating MyDose
  • Table 9.1: SWOT Analysis of the Large volume wearable Injectors Market
  • Table 9.2: List of Available Autoinjectors, 2013
  • Table 9.3: Recall of Autoinjectors
  • Table 9.4: Prefilled Syringe Recalls, 2003-2014
  • Table 13.1: Prevalence of Diabetes, 2013 - By Countries (Million, %)
  • Table 13.2: Large Volume Wearable Injectors: Distribution by Modes of Operation
  • Table 13.3: Large Volume Wearable Injectors: Distribution by Device Usage
  • Table 13.4: Large Volume Wearable Injectors: Distribution by Volume
  • Table 13.5: Total Drugs Market, 2013: Distribution by Nature of Drug (USD Billion, %)
  • Table 13.6: Total Drugs Market Forecast, (2014-2020): Distribution by Biologics and Pharmaceuticals (USD Billion)
  • Table 13.7: Biologic Drugs in Development: Distribution by Type of Molecule (%)
  • Table 13.8: Overall Large Volume Wearable Injectors Market (Number of Devices, Million), 2014 - 2025 - Base Scenario
  • Table 13.9: Overall Large Volume Wearable Injectors Market (USD Million), 2014 - 2025- Base Scenario
  • Table 13.10: Number of Molecules in Large Volume Wearable Injectors for Cancer and Related Conditions, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.11: Large Volume Wearable Injectors Market for Cancer and Related Conditions (Number of Devices, Million), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.12: Number of Molecules in Large Volume Wearable Injectors for Autoimmune Diseases, 2014 -2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.13: Large Volume Wearable Injectors Market for Autoimmune Diseases (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.14: Number of Molecules in Large Volume Wearable Injectors for Blood Disorders, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.15: Large Volume Wearable Injectors Market for Blood Disorders (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.16: Number of Molecules in Large Volume Wearable Injectors for Genetic Disorders, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.17: Large Volume Wearable Injectors Market for Genetic Disorders (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.18: Number of Molecules in Large Volume Wearable Injectors for Infectious Diseases, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.19: Large Volume Wearable Injectors Market for Infectious Diseases (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.20: Number of Molecules in Large Volume Wearable Injectors for Cardiovascular Diseases, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.21: Large Volume Wearable Injectors Market for Cardiovascular Diseases (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.22: Number of Molecules in Large Volume Wearable Injectors for Respiratory Disorders, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.23: Large Volume Wearable Injectors Market for Respiratory Disorders (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.24: Number of Molecules in Large Volume Wearable Injectors for Digestive Disorders, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.25: Large Volume Wearable Injectors Market for Digestive Disorders (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.26: Number of Molecules in Large Volume Wearable Injectors for Musculoskeletal Disorders, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.27: Large Volume Wearable Injectors Market for Musculoskeletal Disorders (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.28: Number of Molecules in Large Volume Wearable Injectors for Diabetes, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.29: Large Volume Wearable Injectors Market for Diabetes (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.30: Number of Molecules in Large Volume Wearable Injectors for Eye Conditions, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.31: Large Volume Wearable Injectors Market for Eye Conditions (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.32: Number of Molecules in Large Volume Wearable Injectors for Skin Diseases, 2014 -2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.33: Large Volume Wearable Injectors Market for Skin Diseases (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.34: Number of Molecules in Large Volume Wearable Injectors for Neurologic Disorders, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.35: Large Volume Wearable Injectors Market for Neurologic Disorders (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.36: Number of Molecules in Large Volume Wearable Injectors for Other Diseases, 2014 - 2025 (Conservative, Base, Optimistic Scenarios)
  • Table 13.37: Large Volume Wearable Injectors Market for Other Diseases (Number of Devices, Millions), 2014 - 2025 (Conservative, Base, Optimistic Scenarios)

List of Companies

The following companies have been mentioned in this report.

  • 1. Abbott Laboratories
  • 2. AbbVie
  • 3. AbGenomics
  • 4. Abingworth
  • 5. Accord Healthcare
  • 6. Acorda Therapeutics
  • 7. Actinium Pharmaceuticals
  • 8. Adaptimmune
  • 9. Aduro Biotech
  • 10. Advanced Technology Ventures
  • 11. Agate Medical Investments
  • 12. Agensys
  • 13. Alder Biopharmaceuticals
  • 14. Alexion Pharmaceuticals
  • 15. Alnylam Pharmaceuticals
  • 16. Altor Bioscience
  • 17. Alverix Inc.
  • 18. AM2PAT Inc.
  • 19. Ambimed
  • 20. Amgen
  • 21. Antaric Pharma
  • 22. Apotex
  • 23. Aramon Neuromedical
  • 24. Ascletis Bioscience
  • 25. Aspen Pharmacare
  • 26. Astellas Pharma
  • 27. Astra Zeneca
  • 28. Athersys
  • 29. Auda Private Equity
  • 30. Aurum Pharmceuticals
  • 31. AVEO Oncology
  • 32. Bang & Olufsen
  • 33. Battelle
  • 34. Baxter International
  • 35. Bayer
  • 36. Becton Dickinson
  • 37. Bespak
  • 38. BioArctic Neuroscience
  • 39. Biodel
  • 40. Biogen Idec
  • 41. BioInvent International
  • 42. BioMarin Pharmaceutical
  • 43. Bluebird bio
  • 44. BMS
  • 45. Boehringer Ingelheim
  • 46. Bracco Diagnostics
  • 47. Calibra Medical
  • 48. Catalyst Biosciences
  • 49. Cato Software Solutions
  • 50. Celgene Cellular Therapeutics
  • 51. Cell Medica
  • 52. Celldex Therapeutics
  • 53. Cellerant Therapeutics
  • 54. Centocor Ortho Biotech, Inc.
  • 55. Central Illinois Angels
  • 56. CeQur SA
  • 57. Children's Hospital Boston
  • 58. CHL Medical Partners
  • 59. Ciradian Technologies
  • 60. Constitution Medical Investors
  • 61. Covidien
  • 62. CSL Behring
  • 63. Cure Tech
  • 64. Cytomedix
  • 65. Cytonet
  • 66. Daiichi Sankyo
  • 67. Daikyo Seiko Ltd
  • 68. Danfoss A/S
  • 69. Dekkun
  • 70. Denderon
  • 71. Eisai
  • 72. Elan Pharmaceuticals
  • 73. Elcam Medical
  • 74. Eli Lilly
  • 75. Elusys Therapeutics
  • 76. Emergent Biosolutions
  • 77. Enable Injections
  • 78. Enbrel
  • 79. Excellium
  • 80. Excelsior Medical
  • 81. FibroGen
  • 82. Five Prime Therapeutics
  • 83. Flugen
  • 84. Future Injection Technologies
  • 85. Genentech
  • 86. Genethon
  • 87. Genia Technologies
  • 88. Geno Pharmaceuticals
  • 89. Genzyme
  • 90. Gilead Sciences
  • 91. GSK
  • 92. GTC Biotherapeutics
  • 93. Halozyme Therapeutics
  • 94. Haselmeier
  • 95. Healthcare Pharmaceuticals(formerly Dekkun)
  • 96. Hemispherx Biopharma
  • 97. Hikma
  • 98. HLM Venture Partners
  • 99. Hospira
  • 100. ImClone Systems
  • 101. Immunomedics
  • 102. Immunovative Therapies
  • 103. InnoKeys PTE
  • 104. INSERM
  • 105. Insulet
  • 106. Ipca Laborataries
  • 107. IQuum
  • 108. Isis Pharmaceuticals
  • 109. J&J
  • 110. Janssen Biologics
  • 111. Janssen Biotech
  • 112. Kaiser Permanente Ventures
  • 113. KaloBios Pharmaceuticals
  • 114. KB Partners
  • 115. Kyowa Hakko Kirin
  • 116. Lincoln Medical Limited
  • 117. MacroGenics
  • 118. MassBiologics
  • 119. MedImmune
  • 120. Medingo
  • 121. Medipac
  • 122. Merck
  • 123. Meridian Medical Technologies
  • 124. Merrimack Pharmaceuticals
  • 125. Milennium Pharmaceuticals
  • 126. Molmed
  • 127. MorphoSys
  • 128. Mpax Phamaceuticals
  • 129. MPM Capital
  • 130. Mylan Pharmaceuticals
  • 131. NeuroDerm
  • 132. Norwich Pharmaceuticals
  • 133. Nourish Pharmaceutical
  • 134. Novartis
  • 135. Novo Nordisk
  • 136. Nuron Biotech
  • 137. Octapharma
  • 138. OncoGenex Technologies
  • 139. OncoMed
  • 140. ONSET Ventures
  • 141. Osiris Therapeutics
  • 142. Owen Mumford
  • 143. Peregrine Pharmaceuticals
  • 144. Pfizer
  • 145. PhaseBio Pharmaceuticals
  • 146. Pitango Venture Capital
  • 147. Pluristem Therapeutics
  • 148. Polyphor
  • 149. Prachi Pharmaceuticals
  • 150. Prometheus Laboratories
  • 151. Protalix Biotherapeutics
  • 152. Prothena Corporation
  • 153. Quintessensce Biosciences
  • 154. Qualitest Pharmaceuticals
  • 155. Ranbaxy Pharmaceuticals
  • 156. Ratio, Inc.
  • 157. rEVO Biologics (formerly GTC Biotherapeutics)
  • 158. Roche
  • 159. Roxane Laboratories
  • 160. Samson Ventures
  • 161. Sandoz
  • 162. Sangamo BioSciences
  • 163. Sanofi Aventis
  • 164. Sanofi Oncology
  • 165. Sanofi Pasteur
  • 166. Sarpeta Therapeutics
  • 167. Sartorius Stedim Biotech
  • 168. Savient Pharmaceuticals
  • 169. Schwarz Pharma
  • 170. Sciele Pharma, Inc.
  • 171. ScPharmaceuticals
  • 172. Seattle Genetics
  • 173. Seattle Medical Technologies
  • 174. Selexys Pharmaceuticals
  • 175. Senesco Technologies
  • 176. Sensile Medical
  • 177. Seragon Pharmaceuticals
  • 178. Shiongi Pharma, Inc.
  • 179. Shire
  • 180. SHL Medical
  • 181. Sillajen Biotherapeutics
  • 182. Spectrum Pharmaceuticals
  • 183. Stateline Angels
  • 184. SteadyMed Therapeutics
  • 185. Sun Pharmaceuticals
  • 186. Synageva BioPharma
  • 187. TaiMed Biologics
  • 188. Takeda Pharmaceuticals
  • 189. Tekmira Pharmaceuticals
  • 190. Teva Pharmaceuticals
  • 191. TG Therapeutics
  • 192. The Golden Angels Network
  • 193. Theraclone Sciences
  • 194. TRACON Pharmaceuticals
  • 195. Tullis Health Investors
  • 196. UCB
  • 197. Unilife
  • 198. United Biomedical
  • 199. United Therapeutics
  • 200. Vaccinex
  • 201. Valeritas
  • 202. VBL Therapeutics
  • 203. Vintage Pharmaceuticals
  • 204. Welsh, Carson, Anderson & Stowe
  • 205. West Pharmaceutical Services
  • 206. Wisconsin Investment Partners
  • 207. Xbiotech
  • 208. Xencor
  • 209. Ypsomed
  • 210. ZZ Biotech
Back to Top